Including mental patterns Lich neoadjuvant
platinum combined with a taxane and finally t, the use of anthracyclines have shown that achieving high PCR in TNBC, but the choice of the drug in this context to the need in the community SSIG be adjuvant anthracyclines and taxanes remain the standard treatment for patients with TNBC breast cancer lymph nodes. The relative sensitivity of anthracycline Roscovitine Seliciclib and taxane resistance in patients with TNBC can nts dependent on the function of the BRCA gene. BRCA loss of sensitivity to chemotherapy resistance and DNAdamaging spindle poisons, such as taxanes and vinca alkaloids on connected. This is not only for BRCA Mutationstr hunter important but sporadic TNBC patients whose tumors have defects in the DNA repair Similar BRCA-associated tumors in this population has been shown that the sensitivity and resistance can be achieved by anthracycline taxane YEARS engined BRCA expression signature to predict.
A recent study has shown that the classical cyclophosphamide, methotrexate, and fluorouracil had a gr Eren benefit of node-negative TNBC patients than in patients with hormone receptor positive or hormone receptor-positive disease’s negative, suggesting FMC can be good choice for adjunctive Lenalidomide therapy in certain Bev lkerungsgruppen. Gegenw Ships there is no standard primarily for use in metastatic disease is recommended. Platinum salts with platinum neoadjuvant chemotherapy is promising because patients triple-negative regimens containing platinum salts with or without other agents were completely pathological’s Full response rate of the best partners platinum agents in the adjuvant setting has not yet been determined, layout showed combined Salts of platinum with epirubicin, adriamycin, taxol, taxotere, and all high PCR in patients TNBC.
Pairing with cisplatin neoadjuvant bevacizumab say completely pathological’s Full response in TNBC patients, although the end limited toxicity t Therapy in about patients. The tumor response to platinum-based drugs metastatic triple negative is also evaluated. Older data for future randomized trials embroidered stripes as NCT, a randomized phase III trial comparing carboplatin and docetaxel as first-line treatment for metastatic triple-negative and recurrent and CALGB, which II neoadjuvant carboplatin and taxane in stage tests and III TNBC are not yet available.
Although the r On this class of drugs in the treatment of patients with TNBC is actively pursued, the systematic use of platinum-containing regimen in patients with early stage TNBC is not recommended. Anti-tubulin Taxanes are taxanes paclitaxel and docetaxel and was effective in all types of breast cancer in both the adjuvant and neoadjuvant TNBC has been shown to have a better response to taxane-containing regimens of chemotherapy that on without taxanes and have a much better response rate neoadjuvant taxane. They prove to be effective TNBC patients in the adjuvant treatment of other subtypes of breast cancer is questionable. The subset analysis of BCIRG tests determined that the benefits of docetaxel dose-independent Ngig of hormone receptor status were. Equally equivocal results between subgroups of hormone receptors were o